CURRICULUM VITAE
May 15, 2001
NAME: ARTHUR BELKNAP STRAUGHN
DATE OF BIRTH: August 10, 1944
PLACE OF BIRTH: Durham, North Carolina
CITIZENSHIP: U.S.A.
MARITAL STATUS: Married August 31, 1968 in Knoxville, Tennessee
Spouse - Maiden Name: Carol Jean Guthe
Date of Birth: June 13, 1946
Place of Birth: Chicago, Illinois
Education: B.S., Human Ecology
University of Tennessee
M.S., Education
Memphis State University
CHILDREN: Tate Lancelot, born February 18, 1977
Christopher Grant, born November 10, 1981
MILITARY SERVICE: U.S. Army 1966-1968
Inactive Reserve 1968-1972
EDUCATIONAL BACKGROUND:
Preparatory : Chapel Hill High School
Chapel Hill, North Carolina
Graduated 1962
Undergraduate : North Carolina State University
Raleigh, North Carolina
University of North Carolina
Chapel Hill, North Carolina
B.S. in Pharmacy, 1972
Post-Graduate : University of Tennessee
Center for the Health Sciences
Memphis, Tennessee
Pharm.D., 1974
Professional Experience:
United States Army Surgery Assistant
September 1966 - July 1968
North Carolina Memorial Hospital Medication Assistant
Department of Nursing June 1971 - May 1972
Chapel Hill, North Carolina
Division of Pharmacy Practice Instructor
School of Pharmacy July 1972 - June 1973
University of North Carolina
Chapel Hill, North Carolina
Department of Medicinal Chemistry Assistant Professor
College of Pharmacy July 1974 - June 1978
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee
Department of Pharmaceutics Assistant Professor
College of Pharmacy July 1978 - June 1979
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee
Department of Pharmaceutics Associate Professor
College of Pharmacy July 1979 - June 1985
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee With Tenure, July 1980
Depart. of Pharmaceutical Sciences Professor and Clinical
College of Pharmacy Director of the Drug
University of Tennessee, Research Laboratory
Memphis July 1985 - present
Memphis, Tennessee Post Tenure Review May 2000
Approved to Direct
Ph.D. September, l990
Course Currently Teaching at UT:
Pharmacokinetics (PHSC 211)
Pharmacokinetic Research Clerkship (PHSC 411)
Memberships in Societies and Associations
(1972-1979) North Carolina Society of Hospital Pharmacists
(1973-1982) American Society of Hospital Pharmacists
(1974- ) American Pharmaceutical Association
(1974- ) Rho Chi, National Pharmacy Honor Society
(1974-1979) Associate Fellow - American College of Apothecaries
(1975- ) Memphis Area Society of Hospital Pharmacists
(1975- ) American Association of Colleges of Pharmacy
(1975- ) American Association for the Advancement of Science
(1981- 1987) Academy of Pharmaceutical Sciences
(1982- ) American College of Clinical Pharmacy
(1984- ) Memphis-Shelby County Pharmaceutical Society
(l985- ) Sigma Xi
(l986- ) Drug Information Association
(1987- ) American Association of Pharmaceutical Scientists
(1989- ) Tennessee Pharmaceutical Association
(1992- ) Phi Lamda Sigma, National Pharmacy Leadership Society
Referee for:
Drug Intelligence and Clinical Pharmacy
American Journal of Hospital Pharmacy
Journal of Pharmaceutical Sciences
Journal of Pharmacokinetics and Biopharmaceutics
Clinical Pharmacy
Pharmaceutical Research
Pharmacotherapy
Reviewer for:
AMA Drug Evaluations
Student Extracurricular Activities:
Student APhA 1970-1972
Drug Abuse Education Committee 1970-1972
Consultantships:
Schering/Key Pharmaceuticals, Inc., Miami, FL
Cord Laboratories, Broomfield, CO
Glaxo Laboratories, Research Triangle Park, NC
Purdue Frederick Company, Norwalk, CT
DuPont Pharmaceuticals, Wilmington, DE
IDR, Inc., Gaithersbug, MD
ClinDAR, Inc., Durham, NC
Martec Pharmaceutical, Inc., Kansas City, MO
Kos Pharmaceuticals, Inc., Miami, FL
The Upjohn Co., Kalamazoo, MI
Pracon, Inc., Reston, VA
Harris Laboratories, Lincoln, NE
Seigfried Pharmaceuticas, Basel, Switzerland
Med. Ed., Inc., Hardford, CN
Carnrick Pharmaceuticals, NJ
Sano/Elan Corporation, Miami, FL
Timerx Technologies, Patterson, NY
Daniels Pharmaceuticals, St. Petersberg, FL
Kemic Research, Canada
Faulding Pharmaceuticals, Adalade, Australia
Anapharma, Canada
Honors and Awards: Teacher of the Year 1991 (Class of 1993)
Elected to Phi Lamda Sigma Pharmacy
Leadership Society 1992
Student Goverment Association Excellence in
Teaching Award 1993
Teacher of the Year 1993 (Class of 1995)
Teacher of the Year 1995 (Class of 1997)
Ancillary Appointments:
College of Pharmacy
Member, Task Force on Professional Practice (1976)
Member, U.T. Statewide Pharmacy Education Program Advisory Committee (1975-1977)
Member, Task Force on Student Cheating (1976)
Academic Student Advisor (1975- )
Member, Task Force on Student Clerkships (1976)
Member, Academic Standing and Promotion Review Committee (1976-1977)
Member, Faculty Advisory Council (1977-1983)
Member, Admissions Committee (1978-1980, 1988-1990)
Member, Curriculum Committee (1980-1985, 1990-1992, 1999- )
Member, Search Committee for Pharmaceutics Chairman (l988-89)
Member, Search Committee for Clinical Pharmacy Chair (l990)
Director, Graduate Admissions in Pharmaceutics (l989-1993)
Member, Promotion and Tenure (l990-1994)
Member, Planning and Assessment (l993-1994)
Member, Technology Assessment (1993-1998)
UT, Memphis
Member, Faculty Senate (1977-1983, 1988- )
Chairman Budget and Benefits (1994- )
Faculty Senate Executive Council (1980-1982)
Graduate Faculty Level to Direct Students (1979- )
Member, Computer Committee (1981-1983)
Chairman, Governance & Credentials Committee (1981-1983)
Board of Directors, UTCHS Faculty Club (1981-1986)
Faculty Senate, Parliamentarian (1982-1983)
Member, Ad Hoc Committee on Faculty Evaluation (1983-1984)
Chairman, Membership Committee, UTCHS Faculty Club(1985-86)
Faculty Counselor to President Boling (1985-1987)
Member, Academic Information Advisory Committee (l988-92)
Chairman (l989-92)
Member, Institutial Review Board (l990- )
Member, UT Parking Authority (l991- )
Member, Ad Hoc Committee Graduate Reserach Council (1992-1993)
Member, UT Student Advisory Council (l993-1995)
Member, UT Campus Support Services (1996 - )
Research Project Director for the following Doctor of Pharmacy
Candidates:
1. Steve K. Huffines 2. Charles D. Rutledge
3. David E. Stewart 4. John Fisher
5. James Eldridge 6. Leslie J. North
7. James F. Koren 8. Sharon Ternullo
9. E. Richard Kessler 10. Trevia Walton
11. Jane Miller 12. Greg Drexler
13. Mike Hayes 14. Dave DiPersio
15. Robert Henderson 16. David Butler
17. Diane Drain 18. Desouky F. Fayed
19. Timothy Mickle
Graduate Student Committees
1. Martin K.T. Yau, Pharmaceutics
2. E. Armstrong, Pharmacy Administration
3. R. Rackley, Pharmaceutics
4. V. Vashi, Pharmaceutics
5. Tina Ursic, Pharmacy Administration
6. Denise Ladd, Nursing
7. Reba Roberts, Pharmaceutics
Graduate Students Directed
1. Robbie Kidd
Publications:
1. "A Novel Pharmacokinetic Slide Rule for Dosage Computations", A. B. Straughn, Copyright 1974.
2. "Assurance of Drug Quality (Bioavailability)", J. H. Coleman and A. B. Straughn, Diseases of the Nervous System, 36:63 (1975).
3. "Warfarin Induced Hypoprothrombiremia: Potentiation of Hyperthyroidism", T. Self, M. Weisburst, E. Wooten, A. B. Straughn, and J. Oliver, J.A.M.A., 231:1165 (1975).
4. "Effect of Hyperthyroidism on the Hypoprothrombinemic Response to Warfarin", T. H. Self, A. B. Straughn and M. R. Weisburst, Am. J. Hosp. Pharm., 33:387 (1976).
5. "Bioavailability of Eleven Sulfisoxazole Tablets", G. Slywka, A. P. Melikian, A. B. Straughn and M. C. Meyer, J. Pharm. Sci., 33:387 (1976).
6. "Bioavailability of Eleven Phenytoin Products", A. P. Melikian, A. B. Straughn, G. W.A. Slywka, P. L. Whyatt and M. C. Meyer, J. Pharmacokin. Biopharm., 5:133 (1977).
7. "Drug Interactions Involving Aminosalicylic Acid", M. C. Meyer, T. H. Self and A. B. Straughn, Rev. Drug Interactions, 2:107 (1977).
8. "Estimations of Drug Dosing Regimens with a Pharmacokinetics Slide Rule", A. B. Straughn, C. A. Cruze and M. C. Meyer, Am. J. Hosp. Pharm., 34:197 (1977).
9. "Meprobamate Bioavailability Monograph", M. C. Meyer and A. B. Straughn, J.A.Ph.A., NS17:173 (1977).
10. "Digitalis Intoxication", C. E. Kossman, A. B. Straughn and B. O. McGraw, Tenn. Med. Assoc. J., September 1977, P. 644.
11. "Factors Affecting the Bioavailability of Chlorothiazide in Man", M. C. Meyer and A. B. Straughn, Curr. Ther. Res., 22:573 (1977).
12. "The Relative Bioavailability of Meprobamate Tablets in Man", M. C. Meyer, A. P. Melikian and A. B. Straughn, J. Pharm. Sci., 67:129 (1978).
13. "The Bioavailability of Sulfadiazine Solutions, Suspensions and Tablets in Man", M. C. Meyer, A. B. Straughn, G. Ramchander, J. C. Cavagnol and A. F. B. Mabadeje, J. Pharm. Sci., 67:1659 (1978).
14. "The Influence of Dosage Form on Papaverine Bioavailability", M. C Meyer, R. Gollamudi and A. B. Straughn, J. Clin. Pharmacol., 19:435 (1979).
15. "Simultaneous Determination of Methenamine and Formaldehyde in the Urine of Humans after Methenamine Administration", R. Gollamudi, M. C. Meyer and A. B. Straughn, Biopharm. Drug Dispos., 1:27 (1979).
16. "The Bioavailability of Chlorothiazide Tablets in Man", A. B. Straughn, A.P. Melikian and M. C. Meyer, J. Pharm. Sci., 68:1099 (1979).
17. "A Multiple-Dose Study of Sustained-Release Theophylline and Aminophylline", M. C. Meyer, A. B. Straughn and P. Lieberman, Chest, 78:300 (1980).
18. "Bioavailability of Microsize and Ultramicrosize Griseofulvin Products in Humans", A. B. Straughn, M. C. Meyer, G. Raghow and K. Rotenberg, J. Pharmacokin.Biopharm., 8:34 (1980).
19. "Evaluation of Enzyme Immunoassay, Radioassay, and Radio-immunoassay of Serum Methotrexate, with Liquid Chromatography as a Standard", R. G. Buice, W. E. Evans, J. Karas, C. A. Nicholas III, P. Sidhu, A. B. Straughn, M. C. Meyer and W. R. Crom, Clin. Chem., 26:1902 (1980).
20. "Pharmacokinetics of Propylthiouracil Upon P. O. Administration in Man", H. P. Ringhand, W. A. Ritschel, M. C. Meyer, A.B. Straughn and T. Hardt, Intl. J. Clin. Pharmacol. Ther. Toxicol., 18:3011 (1980).
21. "Urinary Excretion of Methenamine and Formaldehyde: Evaluation of 10 Methenamine Products in Humans", R. Gollamudi, A. B. Straughn and M. C. Meyer, J. Pharm. Sci., 70:596 (1981).
22. "Chloramphenicol Clearance in Infants", G. J. Burckart, F. Barrett, A. B. Straughn, S. R. Ternallo, J. Clin. Pharm., 22:49 (1982).
23. "HPLC Determination of Benzthiazide in Biological Fluids", M. C. Meyer, P. Hwang, A. B. Straughn, K. Rotenberg, Biopharm. Drug Disposition, 3:1 (1982).
24. "Serious Bioavailability Problems With a Generic Prolonged Release Quinidine Gluconate Product", M. C. Meyer, A. B. Straughn, P. Lieberman, J. Jacob, J. Clin.Pharmacol., 22:131 (1982).
25. "Model-Independent Steady-State Volume of Distribution", A. B. Straughn, J. Pharm. Sci., 71:597 (1982).
26. "Serum Salicylate Concentrations Achieved by AspirinAdministered at Six and Twelve Hour Dosing Intervals", C. D. Butler and A. B. Straughn, Clinical Pharmacy, 1:458 (1982).
27. "Relative Bioavailability of Acetazolamide Tablets", A. B. Straughn, R. Gollamudi and M. C. Meyer, Biopharm. Drug Disposition, 3:75 (1982).
28. "Noneffect of Rifampin on Theophylline Disposition in Rabbits", T. H. Self, M. M. Self, J. P. Worden, W. S. Taylor and A. B. Straughn, Res. Comm. Chem.Path. Pharm., 32:921 (1982).
29. "Isoniazid-Induced Alterations in Theophylline Pharmacokintics", J. R. Thompson, G. J. Burckart, T. H. Self, R. E. Brown and A. B. Straughn, Curr. Ther. Res., 32:921(1982).
30. "Bioavailability of Propylthiouracil in Humans", H. P. Ringhand, W. A. Ritschel, M. C. Meyer, A. B. Straughn and B. E. Cabana, J. Pharm. Sci., 72:1409 (1983).
31. "Absorption of Phenobarbital from Tablets and Elixir", M. C. Meyer, A. B. Straughn, G. Raghow, W. L. Schary and K. S. Rotenberg, J. Pharm. Sci., 73:485 (1984).
32. "Plasma Levels of Ethaverine After Oral Administration to Humans", M. C. Meyer, G. Raghow and A. B. Straughn, Biopharm. Drug Dispos., 4:401 (1983).
33. "Bioequivalence, Dose Proportionality and Pharmacokinetics of Naltrexone After Oral Administration", M. C. Meyer, A. B. Straughn, M. Lo, W. L. Schary, C. C. Whitney, J. Clin. Psychiatry, 45:15 (1984).
34. "Effect of Rifampin on Theophylline Disposition", A. B. Straughn, R. Henderson, P. Lieberman, T. H. Self, Ther. Drug Monitoring, 6:153 (1984).
35. "Administration of Theo-Dur Once-A-Day vs. Twice-A-Day," A. B. Straughn, M. C.
Meyer, A. L. Golub, M. A. Gonzalez, In: Sustained Release Theophylline and Nocturnal Asthma,p. 116: Eds. A.F. Isls and P. von Wichert. Excerpta Medica, Amsterdam.
36. "A Chronopharmacokinetic Model for Sustained Release Formulation," A. B. Straughn, M. C. Meyer, A. L. Golub and M. A. Gonzalez, Annual Reviews of Chronopharmacology 1:92 (1985).
37. "Bioavailability of Dyphylline and Dyphylline-Guiafenesin Tablets in Humans," A. B. Straughn, G. C. Wood, G. Raghow and M.C. Meyer, J. Pharm. Sci. 74:335 (1985).
38. "Comparison of High Pressure Liquid Chromatography and Fluorescence Polarization Immunoassay Methods in a Theophylline Pharmacokinetic Study," R. L. Lalonde, M. B. Bottorff and A. B. Straughn, Ther. Drug Monitoring, 7:442 (l985).
39. "Determination of Free Disopyramide Plasma Concentrations Using Ultrafiltration and EMIT," G. Raghow, M.C. Meyer and A.B. Straughn. Ther. Drug Monitoring, 7:467 (l985).
40. "Bioavailability of Seven Furosemide Tablets in Man," A. B. Straughn, G. C. Wood, G. Raghow, and M. C. Meyer, Biopharm. Drug Dispos. 7:113 (l986).
41. "Dialzability and Pharmacokinetics of Indomethacin in Adult Patients with End- Stage Renal Disease," V.A. Skoutakis, C. Carter, N.J. Wojciechowski, A.B. Straughn, and M.C. Meyer. Drug Intelligence and Clin. Pharm., 12:956 (l986)
42. "Comparison of High Pressure Liquid Chromatography and Fluorescence Polarization Immunoassay to Assess Quinidine Pharmacokinetics," M.B. Bottorff, R.L. LaLonde, and A.B. Straughn. Biopharm. Drug Dispos., 8:213 (1987).
43. "Effect of Food on Absorption of Cefuroxime Axetil," A.B. Straughn, D.A. Finn, and M.C. Meyer. Biopharm. Drug Dispos., 8:519 (l987).
44. "Influence of a Standard Meal on the Absorption of a Controlled-Release Pseudoephedrine Suspension," D.A. Graves, M.T. Wecker, M.C. Meyer, A.B.Straughn, L.P. Amsel, O.N. Hinsvark, A.E. Bhargava and K.S. Rotenberg. Biopharm.and Drug Dispos., 9:267 (l988).
45. "The Absorption of Sustained-Release Methylphenidate Formulations Compared to an Immediate-Release Formulation," K.S. Partick, A.B. Straughn, E.J. Jarvi, G.R. Breese and M.C. Meyer. Biopharm. and Drug Dispos. 10:165 (1989).
46. "A Circadian Rhythm in Theophylline Disposition During a Constant-RateIntravenous Infusion of Aminophylline in the Dog," R.J. Rackley, M.C. Meyer and A.B. Straughn. J. Pharm. Sci. 77:658 (l988).
47. "Chronopharmacokinetic Simulation of a Circadian Rhythm in Theophylline Disposition During a Constant-Rate Intravenous Infusion of Aminophylline in theDog," R.J. Rackley, A.B. Straughn and M.C. Meyer, Ann. Review of Chronopharmacology (1988).
48. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Oxybutynin Using aDeuterated Internal Standard," K.S. Partick, J.S. Markowitz, E.J. Jarvi and A.B.Straughn, M.C. Meyer, J. of Chromatogrtaphy 487:91 (l989).
49. "In Vitro and In Vivo Evaluation of Seven 50mg and 100mg Nitrofurantoin Tablets," M.C. Meyer, G.C. Wood and A.B. Straughn, Biopharm. and Drug Dispos. 10:321(l989).
50. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Nifedipine" K.S.Patrick, E.J. Jarvi, A.B. Straughn and M.C.Meyer, J. Chrom. (Biomed. App.) 495:123(l989)
51. "The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet," C.J. Betlach, A.B. Straughn, M.C. Meyer, M. Bailer, V.I. Vashi, P. Lieberman and M.A.Gonzalez, Pharm. Res. 8:1512 (1991).
52. "Circadian Rhythms in Theophylline Disposition: Simulations and Observations in the Dog," R.J. Rackley, M.C. Meyer and A.B. Straughn, J. Pharm. Sci. 50:835 (l991).
53. "Postmenopausal Steroid Replacement with Micronized Dehydroepiandrosterone (DHEA): Preliminary Oral Bioavailability and Dose Proportionality Studies," J.E. Buster, P.R. Casson, A.B. Straughn, et al, Am. J. Obstet. Gynecol. (in Press).
54. "The Bioinequivalence of Carbamazepine Tablets with a Historyof Clinical Failures," M.C. Meyer, A.B. Straughn, et al, Pharm. Res. 9:1612 (l992).
55. "Quantitative Detrmination of Cyclobenzaprine in Human Plasma by High Pressure Liquid Chromatography," P.T.R. Hwang, D.A.Young, A.B. Straughn, M.C. Meyer, J. Liquid Chrom. 16:1163(1993).
56. "The Effect of Gastric pH on the Absorption of Controlled-Release Theophylline forms in Humans,” M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, V.I. Vashi, P. Hepp, and J. Hunt, Pharm. Res. 10:1037(1993).
57. "Biopharmaceutical Factors in Seizure Control and Drug Toxicity,” M.C. Meyer and A.B. Straughn, Am J. Hosp. Pharm. 50:S17 (1993).
58. "Comparative Steady-State Bioavailability of Theo-24 and Theo-Dur in Healthy Men,” G. Cefali and A.B. Straughn, Ann. Allergy, 72:218 (1994).
59. "Oral Dehydroepiandrosterone in Physiologic Doses Modulates Immune Function in Postmenopausal Women,” P.R. Casson, R.N. Andersen, H.G. Herrod, F.B. Stentz, A.B. Straughn, G.E. Abraham, and J.E. Buster, Am. J. Obstet. Gynecol., 169:1536 (1993).
60. "Effect of Meals and Dosage-Form Modification on Theophylline Bioavailability from a 24-Hour Sustained-Release Delivery System,” M.A. Gonzalez and A.B. Straughn, Clinical Therapeutics, 16:804 (1994).
61. "Pharmacokinetic Comparison of a Once-Daily and Twice-Daily Theophylline Delivery System,” M.A and A.B. Struaghn, Clinical Therapeutics, 16:686 (1994).
62. "Replacement of Dehyroepiandrosterone Enhances T-Lymphocyte Insulin Binding in Postmenopausal Women,” P.R. Casson, L.C. Faquin, F.B. Stentz, A.B. Straughn, R.N. Andersen, G.E. Abraham, and J.E. Buster, Fertility and Sterility 63:1027 (1995)
63. "'Pavlovian’ Food Effect on the Enterohepatic Recirculation of Piroxicam,” J.E. Polli, S. Bigora, D. A. Piscitelli, A.B. Straughn, and D. Young, Biopharm. Drug Disp. 17:635 (1996).
64. "Lack of In Vivo/In Vitro Correlations for 50 mg and 250 mg Primidone Tablets,” M.C. Meyer, A. B. Straughn, R.M. Mhatre, V. Shah, R.L. Williams and L. Lesko, Pharm. Res. (1998).
65. "The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets,” Meyer, MC, Straughn, AB, Mhatre, R, Shah, V, Williams, RL and Lesko, L., Pharm. Res. 15:1787-1791(1998)
66. “The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets”. Meyer, MC, Straughn, AB, Mhatre, R, Shah, V, Williams, RL and Lesko, L., Pharm. Res. 15:1787-1791 (1998).
67. "Pharmacokinetics of Chlorpheniramine, Phenytoin, Glipizide and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele,” Kidd, RS, Straughn, AB, Meyer, MC, Blaisdell, J, Goldstein JA, Dalton JT. Pharmacogenetics 9:71-80 (1999).
68. "Bioequivalence of Methylphenidate Immediate-Release Tablest Using a Replicate Study Dosing to Characterize Intrasubject Variability,” Meyer, MC, Straughn, AB, Jarvi, EJ, Partick, KS, Pelsor, FR, Williams, RL, Patnaik, R, Chen, M, Shah, VP. Pharm. Res. 17:381-384 (2000).
69. "The Effect of Gelatin Cross-Linking on the Bioequivalence of Hard and Soft Gelatin Acetaminophen Capsules,” Meyer, MC, Straughn, AB, Mhatre, R, Hussain, A, Sha, VP, Bottom, C, Cole, E, Lesko, L, Malinoski, H, Williams, RL. Pharm. Res. 17:962-6 (2000)
69. "Bioequivalence of Immediate-Release Theophylline Capsules,” Meyer, MC, Jarvi, EJ, Straughn, AB, Pelsor, RP, Williams, RL, Shah, VP. Biopharm. Drug Disp. 20:417-19 (2000).
70. “Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive.” Veng-Pedersen P, Gobburu JV, Meyer MC, Straughn AB. Biopharm Drug Dispos. 2000 Jan;21(1):1-6.
71. “Variability in the Bioavailability of Phenytoin Capsules in Males and Females. Meyer, MC, Straughn, AB, Mhatre, RM, Shah, VP, Chen, ML, Williams, RL and Lesko, LJ. Pharm. Res. 18:394-397 (2001).
Abstracts:
1. "Use of a Pharmacokinetic Slide Rule in Teaching Pharmacokinetics”, AACP Annual Meeting, Minneapolis, MN, July, 1976.
2. "Effect of Hyperthyroidism on the Hypoprothrombinemic Response to Warfarin", American Pharmaceutical Association Annual Meeting, San Francisco, CA, October, 1975.
3. "Bioavailability of Eleven Sulfisoxazole Tablets", Academy of Pharmaceutical Sciences Annual Meeting, Atlanta, GA, November, 1975.
4. "Bioavailability of Eleven Diphenylhydantoin Capsules", Academy of Pharmaceutical Sciences Annual Meeting, Atlanta, GA, December, 1975.
5. "Bioavailability of Papaverine Dosage Forms", ASHP Mid-Year Meeting, Atlanta, GA, December, 1977.
6. "Bioavailability of Five Warfarin Products in Humans, ASHP Mid-Year Meeting, Las Vegas, NV, December, 1979.
7. "Steady-State Bioavailability of Two Sustained-Release Theophylline Preparations", ASHP Mid-Year Meeting, Las Vegas, NV, December, 1979.
8. "Effect of DOSS on the Absorption of Orally Administered Digoxin", ASHP Mid-Year Meeting, San Francisco, CA, December, 1980.
9. "Pharmacokinetic Analysis with Statistical Moments", ASHP Mid-Year Meeting, San Francisco, CA, December, 1980.
10. "Comparison of Six and Twelve Hour Dosing of Aspirin", ASHP Mid-Year Meeting,
San Francisco, CA, December, 1980.
11. "In Vitro Predictors of Theophylline Bioavailability I: Correlations Between Fraction Dissolved and Fraction Absorbed", Academy of Pharmaceutical Sciences, Orlando, FL November, 1981.
12. "In Vitro Predictors of Theophylline Bioavailability II: Correlations with Statistical Moments", Academy of Pharmaceutical Sciences, Orlando, FL November, 1981.
13. "Hemoperfusion in Theophylline Toxicity", ASHP Mid-Year Meeting, New Orleans, LA, December, 1981.
14. "Pharmacokinetics of Ceftazidime in Normal Subjects and EndStage Renal Disease", Interscience Conference on Antimicrobial Agents and Chemotherapy", Miami Beach, FL October, 1982.
15. "Ceftazidime Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis (CAPD) and Intermittent Peritoneal Dialysis (IPD)", American College of Clinical Pharmacy, Washington, D.C., July, 1983.
16. "In Vitro Prediction of Steady-State Fluctuations in Theophylline Concentrations", American College of Clinical Pharmacy, Washington, D.C., July, 1983.
17. "A Chronopharmacokinetic Model for Sustained-Release Formulations", First International Montreaux Conference: Biological Rhythms and Medications, Montreaux, Switzerland, March, 1984.
18. "Disposition Kinetics of Controlled-Release Theophylline Dosed at 12 and 24 h Dosing Intervals", Academy of Pharmaceutical Sciences, Montreal, Canada, May, 1984.
19. "Bioavailability of Cefuroxime Axetil Administered After Food," Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October, 1984.
20. "Steady-State Aspirin and Metabolite Pharmacokinetics After Administration of Immediate and Controlled-Release Dosage Forms," American College of Clinical Pharmacy, Orlando, FL, July, 1985.
21. "Effect of Gastric pH on the Absorption of Theophylline from Sustained-Release Formulations," American Association of Pharmaceutical Scientists, Boston, MA, June, l987.
22. "Chronopharmacokinetic Simulation of a Circadian Rhythm inTheophylline Disposition During a Constant -Rate Intravenous Infusion of Aminophylline in the Dog," Third International Conference of Chronopharmacology, Niece, France, March, 1988.
23. "Chronopharmacokinetics with Sustained-Release Theophylline,"Third International Conference on Chronopharmacology, Niece, France, March, l988.
24. "Evidence for Circadian Change in Volume of Distribution of Theophylline in the Dog. American Association of Pharmaceutical Scientists, Orlando, FL Nov. l989.
25. "High Fat Meal Effects on the Single Dose Pharmacokinetics of a new Once-a-Day Theophylline Tablet, 45th Annual Congress of the American College of Allergy and Immunology, Los Angeles,CA, Nobember 1988.
26. "Multiple-Dose Pharmacokinetic Evaluation of a Once-Daily Theophylline Tablet Doses to Pediatric Asthmatics", Third Eastern Allergy Conference, Bal Harbour, FL Apr 1990.
27. "Effect of Tablet Halving on the Pharmacokinetics of Theophylline from Uni-Dur", ACCP Annual Meeting, Kansas City, MO, Aug 1990.
28. "Bioavailability of Eight Trichlormethiazide Tablet Formulations," AAPS Annual Meeting, Atlanta, GA, Nov 1989.
29. "Gastric pH and Absorption of Cr-Theophylline Products in Man", AAPS Annual Meeting, Atlanta, GA, Nov 1989.
30. "Bioequivalence of Methylphenidate Tablets", AAPS Annual Meeting, Las Vegas, NV, Nov 1990
31. "Influence of Gastric pH on the Absorption of Diazepam", AAPS Annual Meeting, Las Vegas, NV, Nov 1990.
32. "Bioequivalence of Theophylline Immediate Release Tablets" AAPS Annual Meeting, Las Vegas, NV, Nov 1990.
33. "Multiple Dose Pharmacokinetic Evaluation of a Once Daily Theophylline Tablet Dosed to Pediatric Asthmatics", 3rdEastern Allergy Conference, Bal Harbour, FL 1990.
34. "Pharmacokinetics of Uni-Dur, a Once Daily Theophylline" Annual Conference of the European Respiratory Society, Brussels, Belgium Sept 1991.
35. "Formulation Dependent Steady State Chronopharmacokinetics of Theophylline", AAPS Annual Meeting, Washington, DC, Nov 1991.
36. "The Bioavailability of Multi-Source Amitriptyline Formulations", AAPS Annual Meeting, Washington, DC, Nov 1991.
37. "Effect of Reformulation on the Bioavailability of 50 mg Primidone Tablets", AAPS Annual Meeting, SanAntoino, TX Nov 1992.
38. "The effect of Food on the Bioavailability of Doxycycline Hyclate Capsules and Tablets," Annual Meeting, Orlando, FL Nov 1993.
39. "The Effect of Reformulation on the bioequivalence of 250 mg Primidone Tablets,”AAPS Annual Meeting, Orlando, FL Nov 1993.
40. "Bioequivalence (BE) of Multi_source Carbamazepine (CBZ) Tablets,” AAPS Annual Meeting, San Diego, CA Nov 1994.
41. "Correlation Between In Vitro Dissolution and In Vivo Oral Bioavailability of Piroxicam (PR) Capsules,” AAPS Annual Meeting, San Diego, CA Nov 1994.
42. "Pavlovian Food Effect on Enterohepatic Recirculation Monitored by Drug Plasma Concentration: Piroxicam Example,” AAPS Annual Meeting, San Diego, CA Nov 1994.
43. "Use of the Heidelberg Capsule to Evaluate the Effects of Food on the Bioavailability of an Enteric-Coated Tablet with Rapid Abosrption and Elimination,” AAPS Annual Meeting, San Diego, CA Nov 1994.
44. "Bioequivalence(BE) of Different Lots of Dilantin,” AAPS Annual Meeting, Seattle, WA Oct 1996.
46. "Bioequivalence(BE) of Marketed Multisource Desipramine (DE) Products and the Effects of Gender Differences,” AAPS Annual Meeting, Seattle, WA Oct 1996.
47. "Carbamazepine Level-A In Vitro-In Vivo (VV) Correlation: A scaled Convolution Based Predictive Approach,” AAPS Annual Meeting, Seattle, WA Oct 1996.
48. "The Effects of Cross Linking in Gelatin Capsules on the Bioequivalence of Acetaminophen”, AAPS Annual Meeting, Boston, MA Nov 1997.
49. " The Effect of Hormonal Fluctuation During the Menstrual Cycle on the Pharmacokinetics of Tobramycin”, AAPS Southern Regional Discussion jJGroup, Oxford, MS May 1998.
50. " The Pharmacokinetics of Chlorpheniramine, Phenytoin, Nifepidine and Glipizide in an Individual Homozygous for the LEU359 Allele of CYP 2C90”, AAPS Southern Regional Discussion Group, Oxford, MS May 1998.
51. "Pharmacokinetics of Chlorpheniramine, Phenytoin, Glipizide and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele”, American Association of Pharmaceutical Scientists Annual Meeting November 1998.
52. "Determination of 5-Aminolevulinic Acid (ALA) in Human Plasma Samples by HPLC”, American Association of Pharmaceutical Scientists Annual Meeting November 1998.
53. "Pharmacokinetics Study Comparing RingCapTM Tablets and Matrix Tablets”, Controlled Release Society Annual Meeting May 2000.
Invited Presentations:
1."Digoxin Intoxication: Case Study", Grand Rounds UTCHS, Memphis, Tennessee, Aug, 1976.
2."Pharmacokinetic Considerations in Aminoglycoside Therapy", Arkansas Society of Hospital Pharmacists Fall Seminar, Little Rock, Arkansas, Sept, 1976.
3. "Basic Concepts in Clinical Pharmacokinetics", Seattle Area Society of Hospital Pharmacists Annual Seminar, Seattle, Washington, March, 1977.
4."Bioavailability Aspects of Drug Therapy", Annual St. Thomas Moore-Roche Therapeutic Symposium, Nashville, Tennessee, Aug, 1977.
5."Basic Pharmacokinetics", UTCHS College of Medicine Continuing Education Program, Memphis, Tennessee, March, 1978.
6."The Digitalis Glycosides" and "The Aminoglycosides Antibiotics", Radioassay Applications in Pharmacology and Hematology, Veterans Administration Hospital, St. Louis, Missouri, Apr, 1978.
7."Pharmacokinetic Aspects of Toxicology", Clinical Toxicology and Pharmacology, VA Hospital, Memphis, Tennessee, June, 1979.
8."Drug Dosing Concepts", Clinical Toxicology and Pharmacology, VA Hospital, Memphis, Tennessee, August 27, 1980.
9."A Diurnal Pharmacokinetic Model for Multiple Dose Theophylline", College of Pharmacy, University of Utah, Salt Lake City, Utah, Apr, 1983.
10. "Chronopharmacokinetics", College of Pharmacy, Medica College of Virginia, Richmond, Virginia, May, 1983.
11. "Power Analysis in Bioavailability Studies", Glaxo Laboratories, Research Triangle Park, N.C., Dec, 1983.
12. "Practical Aspects of Therapeutic Drug Monitoring", Winchester County Society of Hospital Pharmacists, Valhalla, N.Y., May, 1984.
13. "Administration of Theo-Dur Once-A-Day vs. Twice-A-Day" Sustained Release Theophylline and Nocturnal Asthma Workshop, Burgenstock, Switzerland, July, 1984.
14. "Interpretation of Bioavailability Data for the Practitioner", ASHP Mid-Year Clinical, New Orleans, LA, Dec, l985.
15. "Controversies in Sustained-Release Theophylline", HamiltonCo. Pharmaceutical Society, Chattanooga, TN, March, l986.
16. "Absorption of pH Dependent SR Theophylline in Patients with Normal and Decreased Gastric Acid Production," Schering Corporation, Miami, FL, June, 1987.
17. "PharMACokinetix: A Pharmacokinetic Simulation Tool, 18thAnnual Meeting of EDUCOM, Los Angles, CA, November, l987.
18. "Bar Code Reading for In-process Quality Control of Clinical Data," 24th Annual Meeting of the Drug Information Association, Toronto, Canada, July 1988.
19. "Pharmacokinetics of a New Once-a-Day Theophylline", 45thAnnual Congress of the College of Allergy and Immunology. LosAngles CA, Nov, l988.
20."Optical Scanning for Clinical Data Capture and Tracking" DIA Workshop on Clinical Data Management, Philadelphia, PA, Apr, 1989.
21. "Pharmacokinetics of 'Once-A-Day' Theophylline, Cancun Conference, Cancun, Mexico, May, l989.
22. "Dosage Regimens for SR Theophylline", 2nd International Colloquium on Progress in Pulmonary Medicine, Deauville, France, June, l989.
23. "Pharmacokinetics of a New Onec-a-Day Theophylline, Medical Education Conference, Dallas, Tx, Sept, l989.
24. "Pharmaceutical Aspects of Theophylline Dosage Forms", Medical Education Conference, Houston, TX, Nov, l989.
25. "Dosing Considerations of Once-a-Day Theophylline, MedicalEducation Conference, New York, NY, Dec, l989.
26. "Bathrooms and Bioinequivalence:Problems with Carbamazepine, Schering Research, Miami, FL, March, l989.
27. "Carbamazepine Bioavailability", Ciba-Giegy, Morristown, NJ, Oct 1990.
28. "Sustained-Release Theophylline", Carnrick Pharmaceuticals, Dallas TX, Apr, 1992.
29. "Ethics and the Industrial/Academic Relationship”, Ethics in Medicine Seminar Series, Memphis, TN, June, 1993.
30."How We Got the Bucks- Pharmaceutical Studies,” A UTRC Hertel Event, Memphis, TN, May, 1994 and April, l995.
31."Pharmacokinetic Workshop Using Stella Simulation Software,” Faulding Pharmaceuticals, Adelaide, Australia, December 1994.
32. "Optomization of Drug Formulations Using In Vitro/In Vivo Modeling with STELLA”, Kemic Course in the Pharmaceutical Scineces Philidelphia PA, May 1997
33. "IVIVC” Tableting Course at UT Memphis, June 1998
34. "SUPAC” Tableting Course at UT Memphis, November 1998
Research Grant Awards:
Co-Investigator U.S. Food and Drug June 1974- $44,850
"Bioavailability Administration June 1975
Evaluation Program"
Co-Investigator State of Tennessee July 1974- $130,000
"Drug Quality Department of June 1975
Assurance Program" Public Health
Co-Investigator U.S. Food and Drug July 1975 $58,000
"Bioavailability Administration June 1976
Evaluation Program"
Co-Investigator State of Tennessee July 1975 $130,000
"Drug Quality Department of June 1976
Assurance Program" Public Health
Co-Investigator U.S. Food and Drug July 1976 $ 53,300
"Bioavailability Administration June 1977
Evaluation Program"
Co-Investigator State of Tennessee July 1976- $ 130,000
"Drug Quality Department of June 1977
Assurance Program" Public Health
Principal Investigator Cooper Laboratories Sept.1976 $ 2,500
"Pharmacokinetics
Use in Developing Theophylline
Dosage Regimens"
Co-Investigator Bell Pharmacal Feb. 1977 $ 8,000
"Bioavailability Studies"
Co-Investigator Cooper Laboratories Mar. 1977 $ 16,000
"Bioavailability Studies"
Co-Investigator Cord Laboratories May 1977 $ 16,000
"Bioavailability Studies"
Co-Investigator State of Tennessee July 1977- $ 130,000
"DrugQuality Department of June 1978
Assurance Program" Public Health
Co-Investigator Cooper Laboratories July 1978 $ 16,200
"Bioavailabiliyv Studies"
Co-Investigator U.S. Food and Drug Sept.1977- $ 271,300
"Bioavailability Administration Aug. 1980
Evaluation Program"
Co-Investigator State of Tennessee July 1978- $ 130,000
"DrugQuality Department of June 1979
Assurance Program" Public Health
Co-Investigator National Cancer Sept.1978- $ 27,500
"Clinical Pharma- Institute - NIH Aug. 1979
cokinetics of Cancer Drugs"
Co-Investigator Cooper Laboratories Oct. 1978 $ 17,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Mar. 1979 $ 7,000
"Sustained-Release
Drug Bioavailability"
Co-Investigator Marion Laboratories Apr.1979 $ 19,200
"Bioavailability Studies"
Co-Investigator Cooper Laboratories June 1979 $ 11,600
"Bioavailability Studies"
Co-Investigator State of Tennessee July 1979- $ 130,000
"Drug Quality Department of June 1980
Assurance Program" Public Health
Co-Investigator Pharmadyne Corp. Aug. 1979 $ 14,800
"Bioavailability Studies"
Co-Investigator Meyer-Glaxo Labs. Dec. 1979 $ 17,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Mar. 1980 $ 25,500
"Bioavailability Studies"
Co-Investigator Meyer-Glaxo Labs. Apr. 1980 $ 24,500
"Bioavailability Studies"
Co-Investigator Berlex Laboratories July 1980 $ 13,000
"Bioavailability Studies"
Co-Investigator State of Tennessee July 1980- $ 130,000
"Drug Quality Department of June 1981
Assurance Program" Public Health
Co-Investigator U.S. Food and Drug Aug. 1980- $ 35,000
"Bioavailability Administration Dec. 1980
Evaluation Program"
Co-Investigator Berlex Laboratories Oct. 1980 $ 9,800
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Jan. 1981 $ 29,600
"Bioavailability Studies"
Co-Investigator Glaxo Laboratories Jan. 1981 $ 41,000
"Bioavailability Studies"
Co-Investigator ord Laboratories Jan. 1981 $ 42,500
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Feb. 1981 $ 22,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals May 1981 $ 5,000
"Bioavailability Studies"
Principal Investigator Bristol-Myers Labs July 1981 $ 1,400
"Aspirin Pharmacokine-
tics in Arthritis"
Principal Investigator Key Pharmaceuticals July 1981 $ 8,000
"Theophylline Bioavail-
ability Studies"
Co-Principal Investigator Key Pharmaceuticals Sept.1981 $ 16,000
"Quinidine Bioavail-
ability Studies"
Co-Investigator Cord Laboratories Jan. 1982 $ 26,000
"Metronidazole Bioavailability
Studies"
Principal Investigator Key Pharmaceuticals Feb. 1982 $ 8,800
"Theophylline Bioavailability
Studies"
Co-Investigator Glaxo, Inc. Feb. 1982 $ 34,300
"Ceftazidime Pharmacokinetics
in Renal Patients"
Principal Investigator Key Pharmaceuticals July 1982 $ 25,000
"Theophylline Bioavail-
ability Studies"
Co-Investigator State of Tennessee July 1982- $ 180,000
"Drug Quality June 1983
Assurance Program"
Principal Investigator Key Pharmaceuticals Aug. 1982 $ 11,800
"Bioavailability Studies"
Co-Investigator Glaxo, Inc. Aug. 1982 $ 15,000
"Ceftazidime Pharmacokinetics
During CAPD"
Co-Investigator Pennwalt Corporation Sept 1982 $ 28,026
"Bioavailability Studies"
Co-Investigator DuPont Corporation Nov. 1982 $ 39,240
"Naltrexone Pharmacokinetics"
Principal Investigator Key Pharmaceuticals Nov. 1982 $ 9,000
"Theophylline Bioavail-
ability Studies"
Co-Principal Investigator Key Pharmaceuticals Nov. 1982 $ 14,000
"Bioavailability Studies"
Co-Principal Investigator Key Pharmaceuticals Dec. 1982 $ 18,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Feb. 1983 $ 36,000
"Multiple Dose Drug Studies"
Co-Principal Investigator Key Pharmaceuticals Feb. 1983 $ 18,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Apr. 1983 $ 22,900
"Theophylline Bioavail-
ability Studies"
Co-Principal Investigator Key Pharmaceuticals July 1983 $ 6,750
"Transdermal Dosing"
Co-Investigator State of Tennessee July 1983- $ 180,000
"DrugQuality Department of June 1984
Assurance Program" Public Health
Co-Principal Investigator Glaxo, Inc. Nov. 1983 $ 59,400
"Food Effect on Cefuroxime"
Co-Principal Investigator International Drug Nov. 1983 $ 65,869
"Aspirin Multiple Dosing" Registration
Co-Investigator Danbury Pharmacal Dec. 1983 $ 31,500
"Bioavailability Studies"
Co-Principal Investigator Purdue Frederick Co. Dec. 1983 $ 28,800
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Jan. 1984 $ 51,000
"Sustained-Release
Theophylline"
Co-Principal Investigator Key Pharmaceuticals Jan. 1984 $ 11,400
"Bioavailability Studies"
Co-Investigator Pfizer Pharmaceuticals Feb. 1984 $ 43,000
"Cefoperazone/Sulbactam"
Principal Investigator Pennwalt Corporation Mar. 1984 $ 5,000
"Bioavailability Studies"
Co-Investigator International Drug Mar. 1984 $ 31,088
"Bioavailability Studies" Registration
Co-Investigator Purdue Frederick Co. Mar. 1984 $ 36,475
"Theophylline Bioavail-
ability Studies"
Co-Principal Investigator Sidmak Laboratory Apr. 1984 $ 24,767
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Apr. 1984 $ 29,330
"Bioavailability Studies"
Principal Investigator Danbury Pharmacal May 1984 $ 23,599
"Bioavailability Studies"
Co-Investigator U.S. Food and Drug June 1984- $ 558,000
"Drug Absorption in Administration June 1987
Achlorhydric Patients"
Co-Investigator State of Tennessee July 1984- $ 180,000
"Drug Quality Department of June 1985
Assurance Program" Public Health
Principal Investigator Key Pharmaceuticals July 1984 $ 23,526
"Theophylline Bioavail-
ability Studies"
Co-Principal Investigator Cord Laboratories July 1984 $ 89,000
"Plasma Binding and Excretion"
Co-Investigator Duramed Pharm. Aug. 1984 $ 16,200
"Absorption Studies"
Principal Investigator Key Pharmaceuticals Aug. 1984 $ 21,266
"Theophylline Bioavail-
ability Studies"
Principal Investigator Key Pharmaceuticals Sept. 1984 $ 22,000
"Absorption Studies"
Co-Investigator Pennwalt Corporation Oct. 1984 $ 36,500
"Bioavailability Studies"
Co-Investigator International Drug Nov. 1984 $ 25,000
"Bioavailability Studies" Registration
Principal Investigator Beecham Laboratories Mar. 1985 $ 46,300
"Temocillin Pharmaco-
kinetics"
Principal Investigator Key Pharmaceuticals Mar. 1985 $ 11,000
"Bioavailability Studies"
Principal Investigator Key Pharmaceuticals Apr. 1985 $ 17,863
"Steady-State Bioavail-
ability Studies"
Co-Investigator State of Tennessee July l985 $ 142,015
"Drug Quality Department of June l986
Assurance Program" Public Health
Principal Investigator Key Pharmaceuticals Aug. l985 $ 20,900
"Theophylline Studies"
Principal Investigator Key Pharmaceuticals Sept.l985 $ 25,600
"Quinidine Studies"
Co-Investigator Quincy Laboratories Sept.l985 $ 67,600
Propranolol/Hydrochlorothiazide"
Co-Investigator Cord Laboratories Oct. 1985 $ 73,000
"Dipyridamole Bioavailability"
Principal Investigator Glaxo, Inc. Dec. l985 $ 19,700
"Cefuroxime Food Studies"
Co-Investigator Colmed Laboratories Jan. l986 $ 32,000
"Dipyridamole Bioavailability"
Co-Principal Investigator Cord Laboratories Apr. l986 $ 86,540
"Single and Multiple Dose
Theophylline Studies"
Co-Investigator State of Tennessee July l986- $ 142,015
"DrugQuality Department of June l987
Assurance Program" Public Health
Co-Investigator Sidmak Laboratories May 1986 $ 67,300
"Griseofulvin Absorption"
Principal Investigator Glaxo Laboratories May l986 $ 18,716
"Ranitidine Studies"
Principal Investigator Key Pharmaceuticals July l986 $ 21,421
"Gastric pH Effect on
Theophylline Absorption"
Principal Investigator Schering Corporation Aug. 1986 $ 16,853
"Single Daily Dosing
for Theophylline"
Co-Investigator Ganes Chemical Co., Jan. l987 $ 23,500
"Bioavailability Study" New York, NY
Co-Investigator Sidmak Laboratories Jan. l987 $ 56,314
"Theophylline Absorption"
Principal Investigator Glaxo, Inc. Jan. l987 $ 22,275
"Theophylline Kinetics"
Principal Investigator Schering Corporation Jan. l987 $ 14,786
Pilot Study on Food Effect
on Theophylline Absorption"
Co-Investigator Beecham Laboratories Feb. l987 $ 70,000
"Pharmacokinetic Study"
Co-Investigator Dinoseb Task Force II Mar. l987 $ 62,500
"Dinoseb Pharmacokinetics"
Principal Investigator Schering Corporation Mar. l987 $ 63,120
"Theophylline Studies"
Co-Investigator Vitarine Mar. l987 $ 32,000
"Dipyridamole Study"
Co-Investigator State of Tennessee July l987 $ 142,015
"Drug Quality Department of June l988
Assurance Program" Public Health
Co-Investigator Sidmak Laboratories May 1987 $ 25,200
"Bioavailability Studies"
Co-Investigator Sidmak Laboratories July l987 $ 97,800
"Steady-State SR Formulations"
Co-Investigator Siegfried AG Aug. 1987 $ 57,600
"Bioreplication Studies"
Principal Investigator Schering Corporation Aug. 1987 $ 30,000
"Theophylline Kinetics at SS"
Co-Investigator US Food and Drug Sept.1987- $ 487,725
"Bioavailability Administration Sept.1990
Evaluation"
Co-Investigator Sidmak Laboratories Oct. 1987 $ 64,500
"Bioavailability Studies"
Principal Investigator Schering Corporation Nov. 1987 $ 43,800
"SR Theophylline Study"
Co-Investigator IDR Jan. l988 $ 34,000
"Aspirin Studies"
Principal Investigator Glaxo, Inc. Jan. l988 $ 28,746
"Re-encapsulated Theophylline"
Principal Investigator Schering Corporation Feb. l988 $ 63,029
"Food Effect SR Theophylline"
Co-Investigator Sidmak Laboratories Mar. 1988 $ 44,200
"Steady-State Study"
Co-Investigator State of Tennessee July l988- $ 142,015
"DrugQuality Department of June l989
Assurance Program" Public Health
Principal Investigator Schering Corporation Sept.1988 $ 17,820
"Theophylline Kinetics"
Co-Investigator Sidmak Laboratories Oct. 1988 $ 30,000
"New Assay Methods"
Principal Investigator Schering Corporation Nov. 1988 $ 23,640
"Theophylline Bioavailability"
Co-Investigator Sidmak Laboratories Nov. 1988 $ 88,000
"Griseofulvin Bioavailability"
Principal Investigator Schering Corporation Dec. 1988 $ 27,930
"Theophylline Bioavailability"
Co-Investigator Vitarine Laboratories Mar. l989 $ 34,000
"Diazepam Studies"
Principal Investigator ScheringCorporation April l989 $ 8,420
"Pediatric Theophylline"
Principal Investigator Kos Pharmaceuticals Apr l989 $ 3,280
"Aspirin Effect on Niacin
Induced Flushing"
Co-Investigator State of Tennessee July l989- $ 106,897
"DrugQuality Department of June l990
Assurance Program" Public Health
Principal Investigator Schering Corporation Nov. 1989 $ 38,960
"Antacids and Theophylline"
Principal Investigator Schering Corporation Dec. 1989 $ 14,850
"Ped S-R Theo Kinetics"
Principal Investigator Schering Corporation Dec. 1989 $ 15,120
"Theophylline Kinetics"
Principal Investigator Schering Corporation Dec. 1989 $ 16,200
"Steady-State Theophylline"
Principal Investigator Schering Corporation Dec. 1989 $ 16,200
"Steady-State Theophylline"
"Principal Investigator Kos Pharmaceuticals Apr. l990 $ 13,220
"New Dosage Forms"
Co-Investigator State of Tennessee July l990- $ 106,897
"DrugQuality Department of June l991
Assurance Program" Public Health
Principal Investigator Schering Corporation July 1990 $ 53,840
"Food Effect on Sprinkle"
Principal Investigator Schering Corporation Aug. 1990 $ 18,389
"Sprinkle/Intact Dosages
Principal Investigator Kos Pharmaceuticals Sep. 1990 $ 31,384
"Food Effect on Absorption"
Principal Investigator Kos Pharmaceuticals Dec. 1990 $ 14,400
"Pilot Effect of Food"
Principal Investigator Venture Pharma. Dec. 1990 $ 6,000
"Flux Studies"
Principal Investigator Schering Corporation Dec. 1990 $ 58,638
"Single Dose Theophylline"
Principal Investigator Schering Corporation Dec. 1990 $ 20,375
"Steady-State Once-a-Day
Theophylline Sprinkle”
Co-Investigator Vitarine Jan. 1991 $ 31,000
"Bioavailability Studies"
Principal Investigator Schering Corporation Jan. 1991 $ 47,082
"Uni-Dur Absorption"
Co-Principal Investigator Hoffman LaRoche Feb. 1991 $ 69,000
"Clonazepam pH Dependent
Absorption"
Co-Prinicpal Investigator Vitarine Feb. 1991 $ 16,300
"Urinary Excretion of NFT
Prinicpal Investigator Schering Corporation Aug. 1991 $ 38,400
"Uni-Dur Analytical"
Co-Principal Investigator MD Pharmaceuticals July 1991 $ 79,488
"Cyclobenzaprine Absorption"
Co-Investigator State of Tennessee July l991- $ 106,695
"DrugQuality Department of June l992
Assurance Program" Public Health
Co-Principal Investigator U.S. Food and Drug July 1991- $ 584,575
"Generic Drug Studies" Administration June 1994
Principal Investigator Kos Pharmaceuticals Oct. 1991 $ 22,507
"Transdermal Drug Delivery"
Principal Investigator Sano Corporation Oct. 1991 $ 12,000
"In Vitro Flux Studies"
Principal Investigtator Sano Corporation Nov. 1991 $ 21,900
"Sport Gel in Women"
Principal Investigator Sano Corporation Apr. 1992 $ 12,072
"In Vivo Flux Study"
Principal Investigator Sano Corporation Apr. 1992 $ 21,900
"Sport Gen in Women II"
Principal Investigator Whitby Research Aug. 1992 $ 31,759
"SR Theophylline Kinetics"
Co-principal Investigator Ciba-Geigy Jan. l993 $ 57,250
"Gastric Emptying and
Enteric Coated Tablets"
Co-principal Investigator Schering-Plough Mar. 1993 $ 83,000
"Antihistamine Pharmacodynamics"
Principal Investigator Kos Pharmaceuticals Apr. l993 $ 36,687
"Absorption of SR Theophylline"
Co-principal Investigator Eon Labs Apr. 1993 $ 170,000
"Multiple Bioavailability Studies"
Principal Investigator Sano Corporation July 1993 $ 28,692
"Transdermal Absorption
of Drugs”
Principal Investigator Timerx Technologies Sept 1993 $ 48,234
"SR Drug Release Properties
in Humans”
Co-principal Investigator Univ. of Maryland July 1993 $ 115,959
"Effect of Formulation Subcontract FDA
on Piroxicam Absorption”
Co-Principal Investigator U.S. Food and Drug July 1994- $ 110,000
"Generic Drug Studies" Administration Jan 1995
Principal Investigator Timerx Technologies Sept 1994 $ 27,970
"SR Albuterol Food Effects
Principal Investigator Timerx Technologies Nov 1994 $ 29,193
"Effect of Food on Pseudoephedrine
Absorption in Humans”
Principal Investigator Sano Corporation Jan 1995 $ 29,156
"Transdermal Absorption
of Drugs in Humans”
Principal Investigator Timerx Technologies Mar 1995 $ 21,956
"Albuterol Absorption”
Principal Investigator Timerx Technologies April 1995 $ 30,736
"Effect of Food on Nifedipine”
Principal Investigator Timerx Technologies April 1995 $ 30,736
"SR Nifedipine Absorpiton
Principal Investigator Timerx Technologies May 1995 $ 34,803
"SR Nifedipine Absorpiton
Principal Investigator Sano Corporation Jan 1996 $ 49,478
"Transdermal Absorption
of Drugs in Humans”
Principal Investigator Timerx Technologies Aug 1995 $ 44,913
"SR Drug Absorption”
Principal Investigator Timerx Technologies Oct 1995 $ 39,714
"Effect of Food on Nifedipine”
Principal Investigator Timerx Technologies Oct 1995 $ 44,913
"SR Nifedipine Absorpiton”
Principal Investigator Timerx Technologies Jan 1996 $ 68,906
"SR Nifedipine Absorpiton”
Principal Investigator Timerx Technologies Jan 1996 $ 39,768
"Effect of Food on Nifedipine”
Co-Investigator Daniels Pharmaceuticals Oct 1995 $ 57,231
"Bioavailability of Dosage Forms”
Co-Investigator Dusa Pharmaceuticals Jan 1996 $ 54,340
"IV vs Oral Dosage Forms”
Principal Investigator Timerx Technologies July 1996 $ 47,583
"Bioavailability of Dosage Forms”
Principal Investigator Timerx Technologies Oct 1996 $ 39,493
"Bioavailability of Dosage Forms”
Principal Investigator Timerx Technologies Nov 1996 $ 114,678
"Bioavailability of Dosage Forms”
Co- Investigator Psoralen, Inc. Dec 1996 $ 16,288
"Bioavailability (Pilot Study)”
Co- Investigator Psoralen, Inc. Dec 1996 $ 59,514
"Bioavailability and Food”
Principal Investigator Timerx Technologies Oct 1997 $ 118,541
"Bioavailability of Dosage Forms”
Principal Investigator Penwest Pharmaceutical Jan 1998 $ 174,645
"Bioavailability of Dosage Forms”
Principal Investigator Sano Corporation Jan 1997 $ 26,290
"Drug Flux Studies”
Principal Investigator Penwest Pharmaceutical July 1998 $ 22,650
"SR Dosage Forms”
Co-Investigator Cogent Pharmaceuticals July 1998 $ 62,205
"Transdermal Drug Deliverly”
Co-Investigator Cogent Pharmaceuticals Nov 1998 $ 99,570
"Transdermal Deliverly in Elderly”
Co-Investigator Selectus Pharmaceuticals Feb 1999 $ 59,850
"Buccal Deliverly System”
Co-Investigator Levotech Pharmaceuticals Mar 1999 $ 21,546
"Contraceptive Drug Deliverly”
Co-Investigator Banner Pharmacaps, Inc. Mar 1999 $ 89,493 "OTC Analgesic Bioavailability”
Prinicpal Investigator Penwest Pharmaceuticals Oct 1999 $ 46,689
"SR Dosage Forms #32
Co-Investigator Alkermes Sept 1999 $ 66,000
"RingCap Dosage Froms”
Co-PI Focus Pharmaceuticals July 1999 $ 13,400
"Isomeric Drug Kinetics”
Co-PI Levotech Pharmaceuticals May 2000 $ 59,702
"Contraceptive Delivery System”
Principal Investigator Penwest Pharmaceuticals Dec 2000 $ 95,230
"Isomeric Drug Kinetics”
Co-PI Focus Pharmaceuticals Feb 2001 $ 67,888
"Isomeric Drug Kinetics”
Co-Principal Investigator U.S. Food and Drug Jan 1995- $ 931,010
"Generic Drug Studies" Administration Jan 2002
Total Funding $ 12,377,883